

IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT2022102 NOVEMBER 17, 2022

IHCP announces pharmacy reimbursement updates for COVID-19 vaccine administration

The Indiana Health Coverage Programs (IHCP) announces updates to pharmacy reimbursement for Bivalent and Novavax vaccines used for the prevention of coronavirus disease 2019 (COVID-19).

COVID-19 Vaccine, Bivalent

As established in *IHCP Bulletin* [BT202279](#), the IHCP provides reimbursement for the administration of COVID-19 bivalent booster vaccine formulations. On Oct. 12, 2022, the U.S. Food and Drug Administration (FDA) [announced](#) that it had amended the emergency use authorizations of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to include a single booster dose in younger age groups. The FDA also announced in this communication that the monovalent Pfizer-BioNTech COVID-19 Vaccine is no longer authorized as a booster for individuals age 5 through 11 years of age.



Effective immediately, for dates of service (DOS) on and after **Oct. 12, 2022**, the IHCP will reimburse IHCP-enrolled pharmacies for the administration of Moderna COVID-19 Vaccine, Bivalent to members age 6 and older and Pfizer-BioNTech COVID-19 Vaccine, Bivalent to members age 5 and older who have completed a primary COVID-19 vaccination series and for whom at least two months has passed since the last vaccine of the series or booster dose. For corresponding updates to COVID-19 vaccination procedure codes, see [BT2022101](#) and subsequent Healthcare Common Procedure Coding System (HCPCS) code updates.

Novavax COVID-19 Vaccine, Adjuvanted

In *IHCP Bulletins* [BT202267](#), [BT202272](#) and [BT202289](#), the IHCP announced reimbursement for the administration of Novavax COVID-19 vaccine, Adjuvanted. On Oct. 19, 2022, with a [recommendation](#) from Centers for Disease Control and Prevention (CDC), the FDA [authorized](#) a booster dose of Novavax COVID-19 Vaccine, Adjuvanted at least six months after completion of a primary vaccination series for individuals ages 18 and older in which one of the following apply:

- An FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate
- The individual receiving would not otherwise receive a booster dose of a COVID-19 vaccine


Effective immediately, for DOS on and after Oct. 19, 2022, the IHCP will reimburse IHCP-enrolled pharmacies for the administration of Novavax COVID-19 Vaccine, Adjuvanted booster doses for members 18 years of age and older.

For more information

COVID-19 vaccination reimbursement is carved out of managed care benefits. Please direct pharmacy-related questions about COVID-19 vaccinations or this bulletin to the OptumRx Clinical and Technical Help Desk by calling toll-free 855-577-6317.

Questions regarding pharmacy benefits unrelated to COVID-19 vaccinations for members in the Healthy Indiana Plan (HIP), Hoosier Care Connect and Hoosier Healthwise should be referred to the managed care entity (MCE) with which the member is enrolled. For information on nonpharmacy questions about COVID-19 vaccinations or this bulletin, contact Gainwell Technologies at 800-457-4584.

For information related to all IHCP-covered COVID-19 vaccine products, please visit the *COVID-19 Vaccination Information* page under the Preferred Products tab on the [OptumRx Indiana Medicaid website](#).



TO PRINT

A [printer-friendly version](#) of this publication, in black and white and without photos, is available for your convenience.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the [Bulletins](#) page of the IHCP provider website at in.gov/medicaid/providers.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at in.gov/medicaid/providers.

